5) Instead of CD20, plasma cells express the CD38 protein on their surface. By using daratumumab, which targets CD38, researchers hope to kill these plasma cells and stop the production of autoantibodies.
Results from the pilot study were promising:
frontiersin.org
Frontiers | Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study
BackgroundMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) entails low quality of life for patients and massive societal costs. There is an urgent...